gauthier_therapy

001 vs placebo tnd 2005 galantamine maintains

Info iconThis preview shows page 1. Sign up to view the full content.

View Full Document Right Arrow Icon
This is the end of the preview. Sign up to access the rest of the document.

Unformatted text preview: label phase Month 12 Month 6 (194) (183) (173) (158) (146) (388) (354) (319) (285) (275) * p < 0.001 vs placebo. © TND 2005 Galantamine maintains Disability Galantamine Assessment for Dementia (DAD) scores Assessment in DAD from baseline Mean (± SE) change Galantamine 24 mg/day Placebo Improvement 2 1 0 -1 -2 -3 -4 -5 -6 Baseline * * p ≤ 0.002 vs placebo Deterioration 2 4 Time (months) 6 © TND 2005 Galantamine improves Neuro-Psychiatric Inventory (NPI) scores over 6 months Inventory Mean (± SE) change in NPI from baseline -2 Improvement -1 * 0 * p = 0.016 vs placebo 1 2 0 Baseline 2 4 6 Time (months) Galantamine 24 mg/day Deterioration Placebo © TND 2005 CI FOR VASCULAR DEMENTIA CI EVIDENCE: three RCT with donepezil and with galantamine showing efficacy in patients with AD & CVD or probable VaD CONTROVERSY: are CI acting on the AD component of VaD? RECOMMENDATION: treat vascular risk factors in all patients with dementia, consider a CI in mixed AD­VaD; need for more RCT in probable VaD © TND 2005 © TND 2005 DI...
View Full Document

This document was uploaded on 03/07/2014 for the course BIOLOGY BIO at NYU.

Ask a homework question - tutors are online